Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trabectedin study in hormone receptor-positive, HER2-negative advanced breast cancer by XPG expression
2010-022968-13Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Jan 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trabectedin in breast cancer, sponsored by PharmaMar. Primary endpoint: Progression-free survival rate at 16 weeks. Started Jan 2011; status: completed.
02
Drugs
trabectedin
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2010-022968-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022968-13.